Why Aldeyra Therapeutics' Shares Are Soaring Today?

  • Aldeyra Therapeutics Inc's ALDX Phase 3 TRANQUILITY-2 trial of reproxalap for dry eye disease has achieved the primary endpoint.
  • Reproxalap was statistically superior to the vehicle for each of the two prespecified primary endpoints, Schirmer test and ≥10 mm Schirmer test responder proportions after a single day of dosing. 
  • The Schirmer test, a measure of ocular tear production, is the dry eye disease objective sign most commonly utilized for drug approval.
  • Related: Aldeyra's Dry Eye Candidate Tops Vehicle In Post-Hoc Analysis Using Computer Automated Grading In Ocular Redness.
  • A Type B Pre-NDA meeting will be held with the FDA in Q3 of 2022, followed by a potential NDA submission, pending enrollment in the ongoing 12-month safety trial and results from a dry eye chamber crossover trial. 
  • Enrollment in the crossover dry eye disease trial is complete, and results are expected in Q3 of 2022. 
  • Price Action: ALDX shares are up 12.2% at $3.60 during the market session on the last check Wednesday.
Loading...
Loading...
ALDX Logo
ALDXAldeyra Therapeutics Inc
$2.940.34%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
13.34
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Comments
Loading...